Epstein-Barr virus (EBV)-associated T/NK-cell lymphoproliferative disease (LPD) has been linked to several different disorders, including chronic active EBV infection, EBV-associated hemophagocytic syndrome, hypersensitivity to mosquito bites, hydroa vacciniforme, aggressive NK-cell leukemia, and nasal/nasal-type NKcell lymphoma. In most instances, these disorders are refractory to conventional treatments and have a poor prognosis. Here, we report a new treatment strategy for EBV-associated T/NK-cell LPD, consisting of immunochemotherapy, intensive combination chemotherapy, and stem cell transplantation. The five patients studied, two with T-cell and three with NK-cell LPD, lacked a human leukocyte antigen-matched, related donor, and therefore received bone marrow grafts from HLA-matched, unrelated donors. The preconditioning regimen consisted of total-body irradiation (12 Gy), etoposide (900 mg/m 2 ), and cyclophosphamide (120 mg/kg) or melphalan (210 mg/m 2 ). All patients had residual LPD by a quantitative PCR technique prior to transplantation. After unrelated bone marrow transplantation (UBMT), four of the five patients remain in continuous complete remission at a median of 19 months, without detectable EBV-DNA in peripheral blood. Thus, UBMT appears to be a reasonable option for the treatment of patients with EBV-associated T/NK-cell LPD. Detection of EBV-DNA by PCR offers an important tool for assessing minimal residual disease in patients with EBV-associated T/NK-cell LPD.
Epstein-Barr virus (EBV) has a tropism for B-cells and is a causative agent of B-cell lymphoproliferative diseases (LPD), such as infectious mononucleosis, African Burkitt lymphoma and post-transplant LPD. 1, 2 In 1988, Jones et al 3 first reported that EBV could infect T-cells and contribute to lymphomas in patients with chronic active EBV infection (CAEBV). Similarly, in 1989, Kawa-Ha et al 4 first reported that EBV is causatively involved in clusters of differentiation CD3-negative LPD (natural killer-cell (NK-cell) LPD). Subsequently, EBV-associated T/NK-cell LPD was linked to EBV-associated hemophagocytic syndrome (EBV-HPS), peripheral T-cell leukemia, aggressive NK-cell leukemia and nasal/nasal-type NK-cell lymphoma. 2 More recently, Ishihara et al 5 reported a close relationship between hypersensitivity to mosquito bites and EBV-associated NK-cell LPD, while Iwatsuki et al 6 showed that hydroa vacciniforme was characterized by the infiltration of EBV-infected T-cells. Despite their heterogeneity, the diseases associated with EBV-infected T/NK-cells generally have a poor outcome. CAEBV, for example, is characterized by chronic or recurrent infectious mononucleosis-like symptoms, abnormal patterns of anti-EBV antibodies, and a high EBV load in peripheral blood mononuclear cells, mostly associated with T or NK cells. The prognosis of patients with CAEBV is very poor. T/NK-cell LPD, hepatic and cardiac failure, opportunistic infection, and hemophagocytic syndrome (HPS) are the main causes of death. 7 Interestingly, one-third of the patients have shown hypersensitivity to mosquito bites, characterized by intense local skin symptoms, consisting not only of erythema or bulla, but also of ulceration or scarring, and general symptoms such as high fever. The skin lesions resemble angiocentric lymphoma infiltrated by EBV-infected NK cells. Patients with hypersensitivity to mosquito bites tend to develop HPS, and their prognosis is very poor. 5 Typical hydroa vacciniforme is defined by photosensitivity, childhood onset, resolution by early adult life, and histologic epidermal necrosis with lymphocyte infiltration. However, the atypical form presents with fever, liver dysfunction, edematous swelling of the face, unusual skin lesions, and progression to subcutaneous lymphoma accompanied by HPS. 6 On the strength of these findings, we have proposed that EBV-associated T/NK-cell LPD is a distinct disease entity. 2, 8 These diseases occur at any age and in both sexes.
Various treatments for EBV-associated T/NK-cell LPD, such as immunoregulatory drugs, antiviral agents, EBVspecific cytotoxic T lymphocytes, and cytotoxic drugs have been investigated without encouraging results. Thus, to reduce and eliminate EBV-infected T/NK-cells, we have devised a new strategy consisting of three phases of treatment: immunochemotherapy, intensive combination chemotherapy, and stem cell transplantation (SCT). We previously reported the successful use of SCT from a human leukocyte antigen (HLA)-matched related donor in a patient with CAEBV. 9 Here, we report on five patients who lacked HLAmatched related donors and were treated with HLAmatched unrelated bone marrow transplantation (UBMT). Four of the patients achieved complete remission without any EBV-DNA detected in the peripheral blood mononuclear cells (PBMNCs) by polymerase chain reaction (PCR). This result suggests that patients with EBVassociated T/NK-cell LPD may be treated successfully with UBMT when there is no suitable related donor.
Patients and methods

Patients
From January 1999 to December 2000, five patients with EBV-associated T/NK-cell LPD were referred to our institute to receive UBMT because they lacked an HLAmatched related donor. The ages of these two males and three females ranged from 3 to 17 years (median, 7 years). None had a history of immunodeficiency-related illness until the onset of disease.
Samples
All test samples were collected with the informed consent of the patients or their parents. PBMNCs were separated from whole blood on Ficoll-Paque density gradients (Phamacia Biotech, Piscataway, NJ, USA). DNA was extracted from 1-10 Â 10 6 PBMNCs (SepaGene; Sanko Junyaku, Tokyo, Japan).
Qualitative PCR analysis of EBV-DNA
In all, 1 mg of DNA from PBMNCs was amplified to detect an internal repeat region of EBV-DNA (BamHI-W), and the amplified products were separated on an agarose gel and visualized by staining with ethidium bromide. The detection limit of this assay was approximately 20 copies of EBV-DNA/mg of PBMNC DNA. 10 
Quantitation of EBV DNA
A real-time quantitative PCR assay was performed with a TaqMan PCR kit and a Model 7700 Sequence Detector (PE Applied Biosystems, Forster City, CA, USA) equipped with a fluorogenic probe and primers selected in the unique BNRF1 region. The amount of EBV-DNA was calculated as the number of viral DNA copies/mg of PBMNC DNA. The detection limit of this assay was approximately 40 EBV genomes/mg of PBMNC DNA, making it considerably less sensitive than qualitative PCR.
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Analysis of EBV-infected cell populations
To determine which cells harbored EBV, we fractionated the PBMNCs into CD2+, CD3+, CD4+, CD8+, or CD20+ cells using an immunobead method (DynaBeads; Dymal A/S, Oslo, Norway). The fractionated cells were analyzed with qualitative PCR. EBV-infected cell populations were identified according to the quantity of EBV-DNA in each lymphocyte fraction. 12 
Southern blot hybridization
The clonality of EBV-infected cell populations was determined by Southern blotting with an EBV terminal repeat probe after the DNA from PBMNCs was digested with BamH1. 13 The clonality of the T-cell receptor for an antigen (TCRb chain) was determined by Southern blotting after genomic DNA extracted from PBMNCs was digested with BamHI, EcoRV, or HindIII. Treatment strategy before UBMT for EBV-associated T/NK-cell LPD Although every patient underwent different immunochemotherapy before UBMT, these treatments can be considered as three phases. In the first phase, in order to control disease symptoms, patients received prednisolone 1-2 mg/ kg/day, etoposide 150 mg/m 2 /week and cyclosporine 3 mg/ kg/day for 1-2 months. The second phase consisted of additional chemotherapy combined with cyclosporine, as follows: modified CHOP regimen (cyclophosphamide, pirarubicin hydrocloride, vincristine, prednisolone), sequential high-dose ara-C (HDCA) (ara-C 3 g/m 2 every 12 h Â 4 doses, l-asparaginase 6000 U/m 2 Â 1 dose), and high-dose ara-C (ara-C 1.5 g/m 2 every 12 h for 6 days). After reduction of the EBV-infected T/NK cells, UBMT was performed.
Preparative regimen and graft-versus-host disease (GVHD) prophylaxis for UBMT
The preconditioning regimen consisted of total-body irradiation (12 Gy in six fractions), followed by a single dose of etoposide 900 mg/m 2 . Four patients (UPNs 227, 250, 252, and 276) also received cyclophosphamide (60 mg/ kg Â two doses), with mesna (60 mg/kg Â two doses divided into three doses) administered before and 4 and 8 h after each dose of cyclophosphamide. The remaining patient (UPN 248) received two doses of melphalan (140 and 70 mg/m 2 each) to avoid possible cardiovascular complications. Tacrolimus (0.02 mg/kg daily by continuous infusion, beginning on the day before UBMT) and methotrexate (7.5 mg/m 2 ) on days 1, 3, and 6 after UBMT were used to prevent GVHD.
Case reports
The clinical and viral findings in the patients before UBMT are summarized in Table 1 .
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UPN 227
The detailed clinical features of this patient have previously been reported. 14 A 17-year-old female presented with fever, flu-like symptoms and liver dysfunction in November 1998, prompting a diagnosis of infectious mononucleosis. However, bone marrow aspiration revealed a proliferation of immature lymphoid cells (48%) and mature-appearing histiocytes with active hemophagocytosis. Immunologic investigation of bone marrow showed 97% CD2+ cells, 97% CD3+ cells, 34% CD4+ cells, 63% CD8+ cells, 6% CD20+ cells, and 7% CD56+ cells. EBV serologic findings included EBV capsid antigen (VCA)-IgG antibody titer of 1 : 320, VCA-IgM o1 : 10, Early antigens-diffuse (EADR)-IgG 1 : 10 and EB nuclear antigen (EBNA) o1 : 10. A monoclonal population within these bone marrow cells was confirmed by demonstrating TCRb rearrangement and by Southern blot analysis with a terminal repeat probe from the EBV genome. These findings led to the diagnosis of EBV-associated HPS. Although her symptoms were refractory to repeated administration of cyclosporine, etoposide and high-dose methylprednisolone, subsequent treatment with CHOP-E (cyclophosphamide, doxorubicin, vincristine, prednisolone, and etoposide) with cyclosporine, resulted in the normalization of symptoms and abnormal laboratory data. EBV-DNA was, however, detectable in her PBMC by PCR. Since she was refractory to conventional immunochemotherapy and EBV-DNA had been detected after five courses of CHOP-E, she was referred to our hospital to undergo UBMT.
UPN 248
A 4-year-old boy developed fever, blistering and ulceration after a mosquito bite in 1988, and developed liver dysfunction in 1992. Laboratory studies revealed abnormal EBV antibody titers (VCA-IgG, 1 : 2560; EADR-IgG, 1 : 320) and increase in NK cells to 70% in peripheral blood. At that time he was diagnosed as having CAEBV, hypersensitivity to mosquito bites and NK-cell LPD. His symptoms continued despite treatment with steroids, interferon-a, and acyclovir, but did not deteriorate rapidly. In December 1997, a liver biopsy revealed chronic active hepatitis with infiltrating lymphocytes that expressed EBVencoded small nuclear RNAs (EBERs). In April 1999, complex cardiovascular disease developed with an aortic aneurysm, bilateral coronary aneurysm, aortic insufficiency, and tricuspid insufficiency. In September 1999, he was referred to our hospital for further treatment since an HLA-matched, unrelated bone marrow donor was found. Immunologic investigation showed 92% CD2+ cells, 31% CD3+ cells, 61% CD56+ cells, and 13% CD20+ cells in his peripheral blood. EBV was demonstrated in the CD2+ CD3À, and CD19À cells obtained from peripheral lymphocytes. Since SCT was contraindicated because of the large ulcers on his foot, he was treated with etoposide and ara-C. His ulcers became smaller, and he underwent dermatoplasty in November 1999, at which time he complained of ulcer-unrelated severe pain in his legs. There were eight nucleated cells per microliter of cerebrospinal fluid, and the cells were EBV-DNA-positive by PCR analysis. He was treated with prednisolone, and the pain reduced. After treatment with high-dose ara-C to reduce the number of EBV-infected T/NK cells, all laboratory findings, including liver function tests, became normal. Unexpectedly, swelling developed in the patient's left arm. A CT-scan showed a tumor in the triceps muscle, with massive infiltration of EBER-positive non-B-lymphocytes apparent in biopsy samples. After local irradiation for 20 Gy, in June 2000, he underwent UBMT.
UPN 250
A 3-year-old girl presented with liver dysfunction and fever in 1995, and was diagnosed as having hypersensitivity to mosquito bites from her symptoms. In June 1999, EBV serology showed a VCA-IgG antibody titer of 1 : 320, EADR-IgG 1 : 20 and EBNA 1 : 40. Immunologic investigation revealed 91% CD2+ cells, 24% CD3+ cells, 61% CD56+ cells, and 11% CD20+ cells in her peripheral UBMT for EBV-associated T/NK-cell LPD T Okamura et al blood. EBV infection was demonstrated mainly in CD3À, CD19À, and CD56+ cells, an NK cell phenotype. She was diagnosed as having CAEBV with NK-cell LPD and was referred to our hospital for UBMT.
UPN 252
An 11-year-old boy present with hydroa vacciniforme-like eruptions in 1993 that regressed spontaneously. Liver dysfunction, and hydroa vacciniforme-like facial eruptions and abnormal EBV antibody titers (VCA-IgG, 1 : 1280; VCA-IgM, 1 : 10; EBNA, 1 : 10) were noted in 1995, leading to the diagnosis of CAEBV. In June 1997, a skin biopsy specimen showed a large number of lymphocytes that were positive for CD2, CD16 and EBERs, and negative for CD3, CD4, CD8, and CD20. These findings prompted the diagnosis of NK-cell LPD. His symptoms did not improve, so he was referred to our hospital for further treatment. An immunologic investigation revealed 93% CD2+ cells, 33% CD3+ cells, 63% CD56+ cells, and 7% CD20+ cells in his peripheral blood. EBV infection was demonstrated in the CD2+ CD3À CD19À cells obtained from peripheral lymphocytes. He was treated with two courses of CHOP and three courses of high-dose ara-C. Just before UBMT, the EBV load in the PBMNCs decreased and was barely detectable by qualitative PCR. The patients treatment and subsequent disease course are illustrated in Figure 1 .
UPN 276
A 7-year-old girl developed a right nasal obstruction in April 2000. In August 2000, a CT-scan of the paranasal cavity showed complete obstruction of the right nasal cavity by a tumor and thickening of the concha wall of the right paranasal cavity. The tumor was infiltrated by CD4+ and EBER+ lymphoid cells. After a diagnosis of peripheral T-cell lymphoma associated with EBV, she was first treated with chemotherapy for localized T-lymphoblastic non-Hodgkin lymphoma, and in October 2000 local irradiation was started. However, she developed high fever, liver dysfunction and thrombocytopenia in November 2000 and was treated with prednisolone, cyclosporine, and etoposide, resulting in the disappearance of symptoms. When she was referred to our hospital, immunologic investigation revealed 63% CD2+ cells, 62% CD3+ cells, 50% CD4+ cells, 15% CD8+ cells, 6% CD20+ cells, and 6% CD56+ cells in her peripheral blood. EBV infection was demonstrated in the CD2+ CD3+ CD4+ lymphocyte subpopulation. She was then treated with one course of short-term HDCA and one course of HDCA. After chemotherapy, the number of cells containing EBV-DNA remained high.
Results
Post-transplant clinical course
The post-transplant clinical courses of the patients are summarized in Table 2 . One child (UPN 248) died on day 14 of infection and renal failure, which was probably caused by infection and drug-related toxicity, and could not be evaluated for the recovery of neutrophils. An autopsy was not performed. Among the four remaining patients, the time required to achieve neutrophil counts 40.5 Â 10 9 /l ranged from 14 to 27 days, while platelet counts 420 Â 10 9 platelets/l were attained over 19-36 days.
Grade 2 or 4 acute GVHD was observed in two of the four evaluable patients (UPNs 250 and 276, Table 2 ). Both cases were limited to the skin and responded well to methotrexate and prednisolone, without further progression. Chronic GVHD of the skin, developed in a single patient, UPN 227, and was controlled with tacrolimus. Four patients achieved complete remission and have Virologic studies before and after UBMT Virologic findings of the five patients immediately before and after UBMT are summarized in Table 3 . EBV titers of all patients were lowered before UBMT. However, although the EBV-DNA of patient 252 was below the detection limit of quantitative PCR before UBMT ( Figure  1 ), all patients had detectable EBV-DNA by qualitative PCR. Within 100 days of UBMT, EBV-DNA was not detectable in the PBMNCs of three patients (UPNs 227, 250, and 252). The remaining patient (UPN 276) was very weakly positive for EBV-DNA by qualitative PCR within 3 months after UBMT, but has been negative by quantitative PCR until now. Since the virus load was low, the EBVinfected cell population could not be identified. With regard to the subsets of lymphocytes in peripheral blood after UBMT, CD56+ cells increased substantially during immunological recovery, as illustrated by the course of patient 252 (Figure 1 ). However, these CD56+ cells were EBV-negative and rapid recovery of CD56+ NK-cell is common after BMT.
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Discussion EBV-associated T/NK-cell LPD has been noted in EBV-HPS, CAEBV, hydroa vacciniforme, hypersensitivity mosquito bites, T/NK-cell leukemia/lymphoma, and nasal/ nasal-type lymphoma 2,3,5,6 -diseases with a generally poor prognosis. The mortality rate among patients with EBV-HPS is about 40%, 16 while in Japan about 60% of patients with CAEBV die within 4-5 years after the onset of disease. 7 Advanced nasal/nasal-type T/NK-cell lymphoma is fatal in most cases. 17 A successful treatment for EBVassociated T/NK-cell LPD remains to be established. Nasal/nasal-type T/NK-cell lymphoma has been treated as non-Hodgkin lymphoma, 17 and EBV-HPS was recently treated with intensive chemotherapy, with or without SCT. 16 Antiviral or immunomodulating agents, such as acyclovir, gancyclovir, vidarabine, interferon-a, and IL-2, have also been evaluated. 2, 7 Adoptive transfer of EBVspecific cytotoxic T lymphocytes to a patient with CAEBV infection was described in one report. 18 While producing some positive results, these therapeutic measures have had only transient efficiency.
The majority of cases of EBV-associated T/NK-cell LPD are monoclonal by Southern blot analysis of EBV-DNA or TCR or by cytogenetic analysis. 3, 4, 19 In fact, all five of our cases showed monoclonality by Southern blotting. We therefore maintain that such cases are true malignancies rather than reactive LPD or infections and that they should be treated accordingly. Since EBV-associated T/NK-cell LPD usually has a fatal progression, such as secondary HPS leading to multiorgan failure, it is critical to eliminate the EBV-infected T/NK-cells and suppress the macrophages and monocytes activated by these cells. Thus, during the first phase of our treatment strategy, the patient is treated with cyclosporine, prednisolone and etoposide. Both responders and patients who are refractory to the first phase then receive combination chemotherapy including CHOP and HDCA in order to reduce the EBV-infected T/NK-cell population still further. The use of EBV-specific cytotoxic T cells might be considered in this phase 18, 20 instead of combined chemotherapy. However, their specificity for the viral antigens expressed in the tumor cells would have to be ensured. A third phase of SCT is needed to eradicate any residual infected cells and reconstitute normal immunity. There have been some reports of autologous BMT, 21 HLA-matched related BMT, 9, 22 and cord blood transplantation for EBV-associated T/NK-cell LPD, 23 but the efficacy of UBMT for these diseases is still controversial because this procedure has higher risks of severe adverse reactions. 24 We believe that UBMT was justified in our patients because each case of LPD was monoclonal and resistant to either first or second phase treatment. In addition, patient 248 had disease progression with large ulcers and cardiovascular disease; patient 252 UBMT for EBV-associated T/NK-cell LPD T Okamura et al had a diagnosis of angiocentric lymphoma; and patient 276 had nasal T-cell lymphoma with systemic dissemination. As none of the five patients had suitable related donors or cord blood, we decided to treat them with UBMT. Four patients underwent the procedure successfully and are doing well. The other (UPN 248), who died of infection and renal failure, had been treated for 12 years and had severe cardiovascular complications and lymphoma at the time of UBMT. This underscores the importance of the patient's clinical condition at the time of UBMT as a major determinant of clinical outcome.
EBV load can now be readily measured with a real-time PCR assay. 11, 25 There have been reports that patients with CAEBV have a high EBV-load in their PBMNCs. 11 In cases 248, 250, and 276, the viral load before UBMT was still high despite immunochemotherapy. In case 252, the viral load decreased as the patient's symptoms improved before UBMT. After transplantation, EBV-DNA was below the detectable level in all four evaluable cases, indicating a good correlation between the viral load in PBMNCs and clinical symptoms. As, in general, the level of CD56+ cells was remarkably high during the early phase after the SCT, 15 as shown in Figure 1 , we could not evaluate the EBV-infected NK-cells by surface marker analysis with CD56 antibody. In this circumstance, we could assess the existence of EBV-infected cells by PCR. Thus, real-time PCR analysis of EBV-DNA on PBMNCs may be useful not only for the diagnosis of CAEBV, but also for monitoring the effectiveness of therapy, as has been proven effective for the detection of minimal residual leukemia. In our hands, qualitative PCR was more sensitive than quantitative PCR for detecting EBV-DNA. We are therefore using the results of this qualitative analysis to decide whether or not SCT should be performed in patients with EBV-associated T/NK-cell LPD. PCR detection of EBV-DNA is generally considered a justification for SCT.
We conclude that SCT, including UBMT, should be performed in a timely manner in cases of EBV-associated T/NK-cell LPD since treatment of late disease may fail because of disease-associated complications. Ultimately, the application of real-time PCR in this disease may prove as beneficial as PCR detection of minimal residual disease in patients with leukemia. UBMT for EBV-associated T/NK-cell LPD T Okamura et al
